Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Interleukin 33 as a mechanically responsive cytokine secreted by living cells.

Kakkar R, Hei H, Dobner S, Lee RT.

J Biol Chem. 2012 Feb 24;287(9):6941-8. doi: 10.1074/jbc.M111.298703. Epub 2012 Jan 3.

2.

IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system.

Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT.

J Clin Invest. 2007 Jun;117(6):1538-49. Epub 2007 May 10.

3.

IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo.

Carriere V, Roussel L, Ortega N, Lacorre DA, Americh L, Aguilar L, Bouche G, Girard JP.

Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):282-7. Epub 2006 Dec 21.

4.

Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo.

Tahara H, Zeh HJ 3rd, Storkus WJ, Pappo I, Watkins SC, Gubler U, Wolf SF, Robbins PD, Lotze MT.

Cancer Res. 1994 Jan 1;54(1):182-9.

5.

Primary sources and immunological prerequisites for sST2 secretion in humans.

Mildner M, Storka A, Lichtenauer M, Mlitz V, Ghannadan M, Hoetzenecker K, Nickl S, Dome B, Tschachler E, Ankersmit HJ.

Cardiovasc Res. 2010 Sep 1;87(4):769-77. doi: 10.1093/cvr/cvq104. Epub 2010 Apr 2.

PMID:
20363761
6.

Expression and regulation of interleukin-33 in human monocytes.

Nile CJ, Barksby E, Jitprasertwong P, Preshaw PM, Taylor JJ.

Immunology. 2010 Jun;130(2):172-80. doi: 10.1111/j.1365-2567.2009.03221.x. Epub 2010 Jan 11.

7.

Nucleo-cytoplasmic shuttling of Id2, a negative regulator of basic helix-loop-helix transcription factors.

Kurooka H, Yokota Y.

J Biol Chem. 2005 Feb 11;280(6):4313-20. Epub 2004 Nov 24.

8.

Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling.

Seki K, Sanada S, Kudinova AY, Steinhauser ML, Handa V, Gannon J, Lee RT.

Circ Heart Fail. 2009 Nov;2(6):684-91. doi: 10.1161/CIRCHEARTFAILURE.109.873240. Epub 2009 Sep 22.

9.

Special aspects of interleukin-33 and the IL-33 receptor complex.

Martin MU.

Semin Immunol. 2013 Dec 15;25(6):449-57. doi: 10.1016/j.smim.2013.10.006. Epub 2013 Nov 11. Review.

PMID:
24230466
10.

The biology of ST2: the International ST2 Consensus Panel.

Pascual-Figal DA, Januzzi JL.

Am J Cardiol. 2015 Apr 2;115(7 Suppl):3B-7B. doi: 10.1016/j.amjcard.2015.01.034. Epub 2015 Jan 23. Review.

PMID:
25665766
11.

Altered subcellular localization of IL-33 leads to non-resolving lethal inflammation.

Bessa J, Meyer CA, de Vera Mudry MC, Schlicht S, Smith SH, Iglesias A, Cote-Sierra J.

J Autoimmun. 2014 Dec;55:33-41. doi: 10.1016/j.jaut.2014.02.012. Epub 2014 Apr 29.

PMID:
24786898
12.

Expression and effects of IL-33 and ST2 in allergic bronchial asthma: IL-33 induces eotaxin production in lung fibroblasts.

Kurokawa M, Matsukura S, Kawaguchi M, Ieki K, Suzuki S, Odaka M, Watanabe S, Homma T, Sato M, Yamaguchi M, Takeuchi H, Adachi M.

Int Arch Allergy Immunol. 2011;155 Suppl 1:12-20. doi: 10.1159/000327259. Epub 2011 Jun 1.

13.

Murine mast cells secrete and respond to interleukin-33.

Tung HY, Plunkett B, Huang SK, Zhou Y.

J Interferon Cytokine Res. 2014 Mar;34(3):141-7. doi: 10.1089/jir.2012.0066. Epub 2013 Sep 12.

14.

Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice.

Sedhom MA, Pichery M, Murdoch JR, Foligné B, Ortega N, Normand S, Mertz K, Sanmugalingam D, Brault L, Grandjean T, Lefrancais E, Fallon PG, Quesniaux V, Peyrin-Biroulet L, Cathomas G, Junt T, Chamaillard M, Girard JP, Ryffel B.

Gut. 2013 Dec;62(12):1714-23. doi: 10.1136/gutjnl-2011-301785. Epub 2012 Nov 21.

15.

Interleukin-33 biology with potential insights into human diseases.

Palmer G, Gabay C.

Nat Rev Rheumatol. 2011 Jun;7(6):321-9. doi: 10.1038/nrrheum.2011.53. Epub 2011 Apr 26. Review.

PMID:
21519352
16.

A novel interleukin 33/ST2 signaling regulates inflammatory response in human corneal epithelium.

Lin J, Zhang L, Zhao G, Su Z, Deng R, Pflugfelder SC, Li DQ.

PLoS One. 2013 Apr 9;8(4):e60963. doi: 10.1371/journal.pone.0060963. Print 2013.

17.

Inducible IL-33 expression by mast cells is regulated by a calcium-dependent pathway.

Hsu CL, Bryce PJ.

J Immunol. 2012 Oct 1;189(7):3421-9. Epub 2012 Aug 24.

18.

Differential release of chromatin-bound IL-1alpha discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation.

Cohen I, Rider P, Carmi Y, Braiman A, Dotan S, White MR, Voronov E, Martin MU, Dinarello CA, Apte RN.

Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2574-9. doi: 10.1073/pnas.0915018107. Epub 2010 Jan 25.

19.

Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production.

Choi YS, Choi HJ, Min JK, Pyun BJ, Maeng YS, Park H, Kim J, Kim YM, Kwon YG.

Blood. 2009 Oct 1;114(14):3117-26. doi: 10.1182/blood-2009-02-203372. Epub 2009 Aug 6.

20.

Mesenchymal stem cells stimulate protective genetic reprogramming of injured cardiac ventricular myocytes.

Rogers TB, Pati S, Gaa S, Riley D, Khakoo AY, Patel S, Wardlow RD 2nd, Frederick CA, Hall G, He LP, Lederer WJ.

J Mol Cell Cardiol. 2011 Feb;50(2):346-56. doi: 10.1016/j.yjmcc.2010.09.001. Epub 2010 Sep 15.

PMID:
20837021

Supplemental Content

Support Center